Janssen Research & Development has submitted to the FDA a New Drug Application (NDA) for Invokamet XR, a once-daily therapy...
The FDA has approved Invokamet, a fixed-dose combination therapy of Invokana (canagliflozin) and metformin hydrochloride, from Janssen Pharmaceuticals, for first-line...
Janssen Pharmaceuticals announced the FDA has approved Invokamet XR�a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)�for...
The FDA has approved Invokamet (canagliflozin and metformin hydrochloride), from Janssen Pharmaceuticals, in a single tablet, for the treatment of...
Janssen R&D has announced results of a Phase III, randomized study showing that the use of initial combination therapy of...